SCHEMBL14218340

SCHEMBL14218340

Oc1nc2ccccc2nc1NCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 2/20 0.56
KMT2A Q03164 5/20 0.54
KDM4E B2RXH2 2/20 0.54
MAPT P10636 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
LMNA P02545 2/20 0.54
ALDH1A1 P00352 1/20 0.54
PKM P14618 1/20 0.54
UBE2N P61088 1/20 0.54
RCE1 Q9Y256 1/20 0.54
APP P05067 3/20 0.53
PDE5A O76074 3/20 0.53
MEN1 O00255 3/20 0.52
HRH4 Q9H3N8 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
POLB P06746 1/20 0.51
GBA1 P04062 1/20 0.51
ATM Q13315 1/20 0.51
ACHE P22303 3/20 0.50
BCHE P06276 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17432180 0.87 RAD52 (0.65) RAD52KMT2AKDM4EMAPTNPSR1
SCHEMBL7242367 0.77 KMT2A (0.58) RAD52KMT2AKDM4EMAPTNPSR1
SCHEMBL8141827 0.75 HRH4 (0.52) RAD52KMT2AKDM4EMAPTNPSR1
SCHEMBL14218356 0.74 MEN1 (0.51) KMT2AKDM4EMAPTNPSR1LMNA
SCHEMBL29558864 0.73 APP (0.63) RAD52KMT2AKDM4EAPPPDE5A
SCHEMBL29558696 0.73 MEN1 (0.63) RAD52KMT2AKDM4EMAPTNPSR1
SCHEMBL12676871 0.72 LMNA (0.57) RAD52KMT2AKDM4EMAPTNPSR1
SCHEMBL12175837 0.71 RAD52 (1.00) RAD52KMT2AKDM4EMAPTNPSR1
SCHEMBL1787657 0.71 KDM4E (0.68) KMT2AKDM4EMAPTNPSR1LMNA
SCHEMBL14191219 0.71 APP (0.50) RAD52KMT2AKDM4EMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368452-B2 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2008-05-06 US disclosed
US-20070060510-A1 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060510-A1 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors PRSS1, SPINT2, HPN RAD52 4627/4885KMT2A 2442/4885KDM4E 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.